Pharma Stability: Insights, Guidelines, and Expertise
According to ICH Q1A(R2), stability studies must use the same or a representative packaging system intended for marketing. A proper justification is required if an alternate or development packaging is used. The justification:
Click to read the full article.
Multi-layer packaging structures are widely used in pharmaceutical blister packs, sachets, and pouches to provide functional barriers against environmental stressors. These include:
Click to read the full article.
A packaging material is considered “novel” if it:
Click to read the full article.
Risk assessment is not just a regulatory expectation—it’s a critical step to proactively avoid packaging-related stability failures. Proper training ensures teams can:
Click to read the full article.
Common failure modes of packaging materials in stability programs include:
Click to read the full article.
CCIT is the science of ensuring that the container-closure system prevents:
Click to read the full article.
CCIT is essential because:
Click to read the full article.
CCIT equipment qualification consists of three critical phases:
Click to read the full article.
Follow these steps to prepare your helium leak detection equipment:
Click to read the full article.
Regulatory authorities, including the EMA and USFDA, consider documentation as legally binding evidence of pharmaceutical product quality. For CCIT, this includes installation qualification of equipment, validation reports, test results, deviation logs, and analyst training. Missing or poorly recorded CCIT data can lead to:
Click to read the full article.
Don’t leave empty-handed. Watch practical GMP scenarios, inspection lessons, deviations, CAPA thinking, and real compliance insights on our YouTube channel. One click now can save you hours later.